These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27725595)

  • 1. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of MDS: morphology, chromosome abnormalities and genetic mutations].
    Hata T
    Rinsho Ketsueki; 2015 Oct; 56(10):1978-84. PubMed ID: 26458436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic alterations in myelodysplastic syndrome.
    Mihara K; Takihara Y; Kimura A
    Cytogenet Genome Res; 2007; 118(2-4):297-303. PubMed ID: 18000383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
    Harada H
    Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and genetic features of myelodysplastic syndromes.
    Greenberg PL
    Int J Lab Hematol; 2012 Jun; 34(3):215-22. PubMed ID: 22212119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
    Nassereddine S; Nishihori T; Padron E; Mahfouz R; Bazarbachi A; Komrokji RS; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):7-13. PubMed ID: 27771290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetic basis of myelodysplastic syndromes.
    Bejar R; Ebert BL
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):295-315. PubMed ID: 20359627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
    Nagoshi H; Horiike S; Kuroda J; Taniwaki M
    Curr Mol Med; 2011 Nov; 11(8):678-85. PubMed ID: 21902648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics factors associated with myelodysplastic syndromes.
    Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.
    Warlick ED; Smith BD
    Curr Cancer Drug Targets; 2007 Sep; 7(6):541-58. PubMed ID: 17896920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.